GBS-NN2
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for GBS-NN2, covering 2024-07-10 to 2024-07-10. Get the full timeline:
Most recent: Clinical Trial Update: GBS-NN/NN2 (50 µg of Each Fusion Protein [GBS-NN and GBS-NN2] in Combination With 500 µg Aluminum as Alhydrogel®) Given With and Without the Tdap Vaccine in Healthy Non-pregnant Women 18 to 49 Years of Age [Phase 2, Phase 3]